What does PHARMA GONRIEUX do?

PHARMA GONRIEUX is a pharmacy in Viroinval. Private Limited, started on 12 June 2018, 1 establishment.

What is the address of PHARMA GONRIEUX?

The registered office of PHARMA GONRIEUX is located at Rue Jean-Chot, Olloy 72, 5670 Viroinval.

Is PHARMA GONRIEUX still active?

Yes. According to the CBE (30 October 2026) PHARMA GONRIEUX is active, legal situation “Normale toestand”, started on 12 June 2018.

Is PHARMA GONRIEUX registered on Peppol?

Yes, PHARMA GONRIEUX is registered on the Peppol network with ID 0208:0697833935.

What is the enterprise number of PHARMA GONRIEUX?

The enterprise number of PHARMA GONRIEUX is BE0697833935.

When was PHARMA GONRIEUX founded?

PHARMA GONRIEUX was founded on 12 June 2018.

Who are the directors of PHARMA GONRIEUX?

According to the 2025 annual accounts, the directors of PHARMA GONRIEUX are: Marie-Pierre MEIRLAEN, Michaël MOLITOR.

Is PHARMA GONRIEUX a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 12 June 2018; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did PHARMA GONRIEUX make in 2025?

PHARMA GONRIEUX posted a profit after taxes of € 56,436 in financial year 2025.

What is the revenue of PHARMA GONRIEUX?

As a small company, PHARMA GONRIEUX is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 261,102.

How much does an employee at PHARMA GONRIEUX earn?

The average wage cost per full-time employee at PHARMA GONRIEUX was € 70,900 in 2025: staff costs of € 127,644 for 1.8 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PHARMA GONRIEUX have?

According to the 2025 annual accounts, PHARMA GONRIEUX has 1.8 full-time equivalents (FTE).

PHARMA GONRIEUX (Private Limited) - Viroinval

Dossier PHARMA GONRIEUX, printed on 30 October 2026 from databakkes.be/en/0697833935/pharma-gonrieux. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

PHARMA GONRIEUX from Viroinval, company number BE0697833935, closed financial year 2025 with a result of € 56,436 after tax. For that financial year PHARMA GONRIEUX recorded a gross margin of € 261,102 and equity of € 316,532. Compared with financial year 2024, the result moved from € 152 to € 56,436. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 28, 2026.

What it is worth Growing

€ 316,532

▲ 19% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 56,436

▲ € 56,284 vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 137,556

▼ 4% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 5,000 paid out

9 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Full-time equivalents

1.8

▲ 0.2 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 127,644

▲ 53% vs 2024

€ 70,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 5,532

▲ € 4,352 vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 3 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 147,750

▼ 53% vs 2024

€ 59,000 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.

Owed to suppliers

€ 63,807

▼ 39% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 35,090

▲ 120% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 258,644 Gross margin 2022: € 258,644 First fiscal year in the series	€ 153,928 Gross margin 2023: € 153,928 ▼ 40% vs 2022 (€ 258,644) Unfavourable step	€ 152,443 Gross margin 2024: € 152,443 ▼ 1% vs 2023 (€ 153,928) Unfavourable step	€ 261,102 Gross margin 2025: € 261,102 ▲ 71% vs 2024 (€ 152,443) Favourable step	▲ 71%
Profit after taxes	€ 88,238 Profit after taxes 2022: € 88,238 First fiscal year in the series	€ -2,280 Profit after taxes 2023: € -2,280 ▼ € 90,518 vs 2022 (€ 88,238) Unfavourable step	€ 152 Profit after taxes 2024: € 152 ▲ € 2,432 vs 2023 (€ -2,280) Favourable step	€ 56,436 Profit after taxes 2025: € 56,436 ▲ € 56,284 vs 2024 (€ 152) Favourable step	▲ € 56,284
Equity	€ 267,224 Equity 2022: € 267,224 First fiscal year in the series	€ 264,945 Equity 2023: € 264,945 ▼ 1% vs 2022 (€ 267,224) Unfavourable step	€ 265,096 Equity 2024: € 265,096 Unchanged (€ 264,945) Favourable step	€ 316,532 Equity 2025: € 316,532 ▲ 19% vs 2024 (€ 265,096) Favourable step	▲ 19%
Total debts	€ 679,284 Total debts 2022: € 679,284 First fiscal year in the series	€ 640,760 Total debts 2023: € 640,760 ▼ 6% vs 2022 (€ 679,284) Favourable step	€ 529,400 Total debts 2024: € 529,400 ▼ 17% vs 2023 (€ 640,760) Favourable step	€ 413,643 Total debts 2025: € 413,643 ▼ 22% vs 2024 (€ 529,400) Favourable step	▼ 22%
Cash	€ 235,353 Cash 2022: € 235,353 First fiscal year in the series	€ 243,259 Cash 2023: € 243,259 ▲ 3% vs 2022 (€ 235,353) Favourable step	€ 143,626 Cash 2024: € 143,626 ▼ 41% vs 2023 (€ 243,259) Unfavourable step	€ 137,556 Cash 2025: € 137,556 ▼ 4% vs 2024 (€ 143,626) Unfavourable step	▼ 4%
Land & buildings	€ 163,559 Land & buildings 2022: € 163,559 First fiscal year in the series	€ 154,138 Land & buildings 2023: € 154,138 ▼ 6% vs 2022 (€ 163,559) Unchanged	€ 144,717 Land & buildings 2024: € 144,717 ▼ 6% vs 2023 (€ 154,138) Unchanged	€ 59,340 Land & buildings 2025: € 59,340 ▼ 59% vs 2024 (€ 144,717) Unchanged	▼ 59%
Retained profit	€ 248,624 Retained profit 2022: € 248,624 First fiscal year in the series	€ 246,345 Retained profit 2023: € 246,345 ▼ 1% vs 2022 (€ 248,624) Unfavourable step	€ 246,496 Retained profit 2024: € 246,496 Unchanged (€ 246,345) Favourable step	€ 297,932 Retained profit 2025: € 297,932 ▲ 21% vs 2024 (€ 246,496) Favourable step	▲ 21%
Dividend	€ 55,000 Dividend 2022: € 55,000 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 55,000) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 5,000 Dividend 2025: € 5,000 Unchanged (€ 0) Unchanged
Bank debt	€ 454,250 Bank debt 2022: € 454,250 First fiscal year in the series	€ 382,916 Bank debt 2023: € 382,916 ▼ 16% vs 2022 (€ 454,250) Favourable step	€ 311,583 Bank debt 2024: € 311,583 ▼ 19% vs 2023 (€ 382,916) Favourable step	€ 147,750 Bank debt 2025: € 147,750 ▼ 53% vs 2024 (€ 311,583) Favourable step	▼ 53%
Balance sheet total	€ 946,508 Balance sheet total 2022: € 946,508 First fiscal year in the series	€ 905,705 Balance sheet total 2023: € 905,705 ▼ 4% vs 2022 (€ 946,508) Unchanged	€ 794,497 Balance sheet total 2024: € 794,497 ▼ 12% vs 2023 (€ 905,705) Unchanged	€ 730,175 Balance sheet total 2025: € 730,175 ▼ 8% vs 2024 (€ 794,497) Unchanged	▼ 8%
Employees (FTE)	1.5 Employees (FTE) 2022: 1.5 First fiscal year in the series	1.2 Employees (FTE) 2023: 1.2 ▼ 0.3 vs 2022 (1.5) Unchanged	1.6 Employees (FTE) 2024: 1.6 ▲ 0.4 vs 2023 (1.2) Unchanged	1.8 Employees (FTE) 2025: 1.8 ▲ 0.2 vs 2024 (1.6) Unchanged	▲ 0.2

Key figures of PHARMA GONRIEUX, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMA GONRIEUX?

What happened at PHARMA GONRIEUX in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 28, 2026 New annual accounts for financial year 2025: profit of € 56,436 (▲ € 56,284 vs 2024). filed late Source: NBB ↗
Jul 1, 2018 New establishment in Couvin. KBO
Jun 12, 2018 Start of the company according to the CBE. KBO

In short

From € 88,238 profit in 2022 to € 56,436 profit in 2025.

Paid € 30,526 in corporate taxes since 2022.

Best year ever: 2022, with € 88,238 profit.

On average € 145,100 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Marie-Pierre MEIRLAEN Michaël MOLITOR

PHARMACIE MOLITOR-MEIRLAEN

PHARMA GONRIEUX

Behind PHARMA GONRIEUX are Marie-Pierre MEIRLAEN and Michaël MOLITOR. Marie-Pierre MEIRLAEN is also behind PHARMACIE MOLITOR-MEIRLAEN.

Directors

According to the 2025 annual accounts

Marie-Pierre MEIRLAEN

Director

Also active at: PHARMACIE MOLITOR-MEIRLAEN

Michaël MOLITOR

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Jean-Chot, Olloy 72

5670 Viroinval

2.276.751.930

Place Dr-Charles-Briquet, Gon. 3

5660 Couvin

Active since 1 July 2018

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

PHARMACIE MOLITOR-MEIRLAEN same network

€ 355,441 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0697.833.935
VAT number: BE 0697.833.935
Registered office: Rue Jean-Chot, Olloy 72, 5670 Viroinval
Names & denominations: PHARMA GONRIEUX
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 12 June 2018
Peppol: Active · Active since 1 Dec 2025
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗